Literature DB >> 26022561

New generation adjuvants--from empiricism to rational design.

Derek T O'Hagan1, Christopher B Fox2.   

Abstract

Adjuvants are an essential component of modern vaccine development. Despite many decades of development, only a few types of adjuvants are currently included in vaccines approved for human use. In order to better understand the reasons that development of some adjuvants succeeded while many others failed, we discuss some of the common attributes of successful first generation adjuvants. Next, we evaluate current trends in the development of second generation adjuvants, including the potential advantages of rationally designed synthetic immune potentiators appropriately formulated. Finally, we discuss desirable attributes of next generation adjuvants. Throughout, we emphasize that the importance of formulation and analytical characterization in all aspects of vaccine adjuvant development is often underappreciated. We highlight the formulation factors that must be evaluated in order to optimize interactions between vaccine antigens, immune potentiators, and particulate formulations, and the resulting effects on safety, biological activity, manufacturability, and stability.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alum; Emulsion; Formulation; MPL; Vaccine adjuvant

Mesh:

Substances:

Year:  2015        PMID: 26022561     DOI: 10.1016/j.vaccine.2015.01.088

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

2.  Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis.

Authors:  Lucian Visan; Violette Sanchez; Margaux Kania; Aymeric de Montfort; Luis M de la Maza; Salvador Fernando Ausar
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

3.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

Review 4.  [Composition and mode of action of adjuvants in licensed viral vaccines].

Authors:  Ralf Wagner; Eberhard Hildt
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

Review 5.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

6.  Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity.

Authors:  Xu Li; Stephanie Hufnagel; Haiyue Xu; Solange A Valdes; Sachin G Thakkar; Zhengrong Cui; Hugo Celio
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-29       Impact factor: 9.229

7.  Revisiting GM-CSF as an adjuvant for therapeutic vaccines.

Authors:  Weidong Zhao; Gan Zhao; Bin Wang
Journal:  Cell Mol Immunol       Date:  2017-10-23       Impact factor: 11.530

8.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

9.  A poly(beta-amino ester) activates macrophages independent of NF-κB signaling.

Authors:  Neil M Dold; Qin Zeng; Xiangbin Zeng; Christopher M Jewell
Journal:  Acta Biomater       Date:  2017-12-30       Impact factor: 8.947

10.  Dissociation of TRIF bias and adjuvanticity.

Authors:  Katharina Richard; Darren J Perkins; Erin M Harberts; Yang Song; Archana Gopalakrishnan; Kari Ann Shirey; Wendy Lai; Alexandra Vlk; Anup Mahurkar; Shreeram Nallar; Lynn D Hawkins; Robert K Ernst; Stefanie N Vogel
Journal:  Vaccine       Date:  2020-05-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.